Supported by National Natural Science Foundation of China,No.82100625;Zhejiang Provincial natural Science Foundation of China,No.Q20H030013.
BACKGROUND The introduction of pegaspargase has greatly advanced the treatment of acute lymphoblastic leukemia(ALL).In the literature,only one case of pegaspargaseinduced multiple organ failure has been reported,and t...
funded by the National Natural Science Foundation of China grant 81700148 and Natural Science Foundation of Guangdong Province grant 2021A1515010093 and 2023A1515011862;funded by the National Natural Science Foundation of China grant 82170181;funded by the Basic and Applied Basic Research Foundation of Guangdong Province grant 2022B1515120087.
Objectives:The optimal treatment strategy for early-stage natural killer/T-cell lymphoma(NKTCL)remains unclear.This study aimed to evaluate and compare the clinical outcomes and adverse events(AEs)associated with two ...
supported,in part,by research funding from the National Natural Science Foundation of China (82130004 and 82270194);National key research and development program (2022YFC2502600);Chang Jiang Scholars Program,Shanghai Rising-Star Program (23QA1406100);Shanghai Municipal Commission of Science and Technology Project (23141903100);Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support (20152206,20152208,and 20161303);Clinical Research Plan of Shanghai Hospital Development Center (SHDC 2020CR1032B);Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine (DLY201601)。
Natural killer T cell lymphoma(NKTCL)is highly aggressive,with advanced stage patients poorly responding to intensive chemotherapy.To explore effective and safe treatment for newly diagnosed advanced stage NKTCL,we co...
Acute myeloid leukemia(AML)and acute lymphoblastic leukemia(ALL)are distinct subtypes of acute leukemia with respect to clinical and genetic features.Recently,ALLs were reported to share similar genes like IDH1 mutati...
Objective To explore the prognostic factors of extracellular NK/T cell lymphoma(ENKTL)treated with pegaspargase/L-asparaginase.Methods The clinical data of 656 ENKTL patients diagnosed at 11 medical centers in the Hua...
Objective:To compare the effect of L-asparaginase and pegaspargase in the treatment of adult acute lymphoblastic leukemia.Methods:In this study,96 patients who received treatment at the Shaanxi Provincial People’s Ho...
supported by the Union for China Lymphoma Investigators,and funded by the Multicenter Clinical Research Project by Shanghai Jiao Tong University School of Medicine(DLY201601);the National Key R&D Program of China(2022YFC 2502600);the National Natural Science Foundation of China(82130004,81830007,82070204,and 81670176);Chang Jiang Scholars Program,Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support(20152206 and 20152208);the Clinical Research Plan of Shanghai Hospital Development Center(SHDC2020CR1032B);the Collaborative Innovation Center of Systems Biomedicine,and the Samuel Waxman Cancer Research Foundation.
Methotrexate,etoposide,dexamethasone,and pegaspargase(MESA)with sandwiched radiotherapy is known to be effective for early-stage extranodal natural killer/T-cell lymphoma,nasal type(NKTCL).We explored the efficacy and...
National Natural Science Foundation of China(No.82170181);Beijing Hospitals Authority Youth Programme(No.QML20200201);Beijing Natural Science Foundation(No.7222027);CSH Young Scholars and 3SBioPharmaceutical joint research project(No.KYC2201001)
To the Editor:Extranodal natural killer/T-cell lymphoma(ENKTCL)is a highly aggressive lymphoma,closely associated with Epstein–Barr virus(EBV)infection.By using the combination of radiotherapy(RT)and asparaginase-bas...
Objective:To analyze the clinical effect of pegaspargase combined with chemotherapy on patients with lymphoma.Methods:Seventy patients with lymphoma admitted to Shaanxi Provincial People’s Hospital between December 2...
Supported by National Natural Science Foundation of China,No.81871633;Beijing Natural Science Foundation,No.7181003;Beijing Municipal Administration of Hospitals’Ascent Plan,No.DFL20180101.
BACKGROUND Chronic active Epstein-Barr virus infection(EBV)is a systemic EBV-positive lymphoproliferative disease,which may lead to fatal illness.There is currently no standard treatment regimen for chronic active EBV...